美国 · 平台与数据 · Yahoo Finance
Stoke Therapeutics Inc (STOK) Q3 2026 Earnings Call Highlights: Strong Cash Runway and Phase 3 ...
Stoke Therapeutics Inc (STOK) ended Q3 2026 with $358.8 million in cash to fund operations into early 2028, while advancing its Phase 3 EMPEROR study toward top-line data expected…
在 Yahoo Finance 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (finance.yahoo.com)



